Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910011 · ClinicalTrials.gov registry record · Phase 2
Topical NanoDox® for Atopic Dermatitis
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT02910011 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 23 participants.
The verdict
NCT02910011, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will investigate the safety and clinical efficacy of a novel doxycycline topical formulation in subjects with Atopic Dermatitis (AD). The investigators hypothesize that daily application of the study drug in AD subjects will reduce severity of the disease, by reducing skin driven inflammation and restoring skin barrier function. The investigators will also monitor the anti-microbial activity of this product on AD skin, as colonization with Staph aureus is typically associated with disease severity.
Interventions
- DRUG Nanodox 1% (doxycycline monohydrate hydrogel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910011
The ClinicalTrials.gov registry entry for NCT02910011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nanodox 1% (doxycycline monohydrate hydrogel) is the first listed.
NCT02910011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910011 about?
NCT02910011 is a clinical study titled "Topical NanoDox® for Atopic Dermatitis". This study will investigate the safety and clinical efficacy of a novel doxycycline topical formulation in subjects with Atopic Dermatitis (AD). The investigators hypothesize that daily application of the study drug in AD subjects will reduce severity of the disease, by reducing skin driven inflamma...
What is the current status of trial NCT02910011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-05-18. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT02910011?
The interventions under investigation include: Nanodox 1% (doxycycline monohydrate hydrogel) (DRUG).
Who is sponsoring clinical trial NCT02910011?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.